Manufacturing Models Permitting Roll - Out / Scale - Out of Clinically
Led Autologous Cell Therapies: Regulatory and Scientific Challenges for Comparability.
Not exact matches
Additionally, genetic modification or pre-conditioning of
autologous cells to boost the levels of VEGF [4], ANG [5], and TGF -[6], all previously linked to alleviation of ALS symptoms, could potentially
lead to an augmented response, although this must first be assessed in animal models, such as the SOD1 mice.
This is the «show reel» of Dr Haluk Deda, a Turkish neurosurgeon who is setting up shop in Dubai, where he plans to offer
autologous stem
cell transplants to treat chronic spinal cord injuries and ALS, a condition with no known cure that generally
leads to death within three to five years of diagnosis.